In This Section

Michael D. Hogarty, MD
Michael D. Hogarty
Associate Director, Pediatric Hematology/Oncology Fellowship

Dr. Hogarty is a pediatric oncologist with 20 years' experience as a physician-scientist with a careerlong focus on neuroblastoma translational biology.



Subscribe to be notified of changes or updates to this page.

11 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.


Dr. Hogarty's research focuses on the childhood tumor neuroblastoma. Laboratory-based and translational in focus, his research involves using complementary preclinical models to identify the principal pathways used during in the initiation and progression of this cancer, and to better understand the cell’s behaviors and vulnerabilities. His ultimate goal is to translate discoveries in the lab and clinic toward the development of novel treatment approaches for neuroblastoma.

Dr. Hogarty's research focuses on three main areas, the first being how neuroblastoma cells survive all of the stressors they encounter during tumor growth and in response to treatment. Along with his colleagues, Dr. Hogarty developed a unique functional assay to identify the specific stress vulnerabilities for a cancer cell, and used this to select tumors for selective Bcl-2-directed treatments and to study the mechanisms of treatment resistance in general. The emergence of treatment resistance in tumor cells remains a major problem in neuroblastoma.

He is also interested in how the MYCN oncogene drives tumor progression. His work in this area tests numerous polyamine antagonists to see which combinations are most capable of reducing cancer cell polyamines and, importantly, which are most potent in regressing and curing neuroblastomas. To this end Dr. Hogarty employs complementary models using both xenograft-bearing and transgenic tumor-prone mice.

In addition, Dr. Hogarty and his colleagues discovered a novel oncogenic driver pathway in neuroblastoma using whole genome sequencing. Recurring mutations and deregulation in the BAF (Brg1-associated Factors) chromatin remodelling complex are associated with aggressive neuroblastoma behavior. The team is characterizing the function of this pathway in this tumor, how the mutations specifically alter this, and working to develop clinically useful assays to detect such mutations and even target them therapeutically.

Education and Training

BES, Johns Hopkins University (Biomedical Engineering), 1986

MD, Columbia University, 1990

Fellowship, Children's Hospital of Philadelphia (Pediatric Hematology/Oncology), 1997

Titles and Academic Titles

Associate Director, Pediatric Hematology/Oncology Fellowship

Attending Physician

Professor of Pediatrics

Professional Memberships

American Association for Cancer Research

American Society of Clinical Oncology

American Society of Pediatric Hematology/Oncology

Children's Oncology Group

American Board of Pediatrics

International Histiocyte Society

Society for Pediatric Research

Professional Awards

Young Investigator Award, American Society of Clinical Oncology, 1996

Young Investigator Award, Advances in Neuroblastoma Research, 1998

Molecular Approach to Pediatric Science-CHRC Award, 1998

Career Development Award, American Society of Clinical Oncology, 1999

Career Award in the Biomedical Sciences, Burroughs Wellcome Fund, 2000

University Research Foundation Award, 2005

Foerderer-Murray Research Award, 2005

Basic Science Award, Advances in Neuroblastoma Research, 2014

Publication Highlights

Links of Interest